24d agoThe FlyBULLISH 56Earnings
Archived explainer. For the current picture see today's BEAM page.
Why Is BEAM THERAPEUTICS IN (BEAM) Stock Down Today?
By the Top Tier Newswire AI Desk · August 20, 2026 at 9:45 AM ET · reviewed against 2 wire stories
BEAM THERAPEUTICS IN (BEAM) is down -4.74% in the latest session. Our newswire has captured 2 stories on BEAM across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why BEAM stock is down today
BEAM stock fell 4.74% to $27.69 on Tuesday, driven by a mixed earnings report and continued pressure from insiders. The stock opened at $28.96 but quickly lost momentum, hitting a session low of $27.56 before closing at $27.60. The move followed a report of second-quarter earnings of 14 cents per share, which improved from a loss of 28 cents per share in the same period last year. However, the company remains unprofitable with a trailing 12-month net margin of -55.4% and a beta of 2.21, indicating heightened volatility.
What Happened
Beam Therapeutics reported second-quarter 2026 operating results showing a backlog of $5.4 million as of June 30. Gross margin was reported at 17.8%, or 26.2% excluding non-cash depreciation and amortization. The company maintained an unused $100 million credit line. Separately, Beam Therapeutics reported a Q2 EPS of $(1.18), missing the $(1.11) estimate, and revenue of $490,000, missing the $16.37 million estimate. These results, combined with continued executive selling, contributed to the stock’s decline.
What The Data Shows
The stock’s intraday session showed a sharp decline after opening near $29. Volume was 0.3 million shares, which is 0.1 times the 3-month daily average. The stock is currently trading within its 52-week range of $15.60 to $38.26. On August 20, the stock printed one fresh 52-week high and two fresh 52-week lows. Recent insider transactions include four sales totaling $12.2 million over the last 90 days, with the most recent filing on July 29.
What To Watch
Beam Therapeutics is scheduled to present updated clinical data from its Phase 1/2 trial evaluating BEAM-302 for Alpha-1 Antitrypsin Deficiency at the ERS Congress 2026. Investors will also be monitoring coverage breadth and any further developments in the arbitration case involving Prime Medicine.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM by the numbers
Last: $27.69Session: -4.74%7 sessions: +5.74%Coverage: 2 stories / 2 sourcesAI sentiment: 52/100 (mixed)Mkt cap: $2.7B52w: $15.60 to $38.26
The headlines behind the move
24d agoStockTitanNEUTRAL 48Earnings
Beam Global Reports Second Quarter 2026 Operating Results
As of June 30, backlog was $5.4M; gross margin was 17.8%, or 26.2% excluding non-cash depreciation and amortization, while a $100M credit line was unused.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BEAM: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BEAM move explainers: 2026-09-09 · 2026-09-08 · 2026-08-26 · 2026-08-25 · 2026-08-20